Precision BioSciences Doses First Patient in Phase 1/2 DMD Gene Editing Trial
Event summary
- Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD trial on August 24, 2026.
- PBGENE-DMD targets up to 60% of Duchenne muscular dystrophy (DMD) patients with mutations in exons 45-55.
- The trial aims to restore near full-length dystrophin using two ARCUS nucleases delivered via AAV.
- Initial safety data from the trial is expected by year-end 2026.
The big picture
Precision BioSciences' Phase 1/2 FUNCTION-DMD trial represents a strategic shift in DMD treatment, moving beyond synthetic microdystrophin to gene editing that restores near full-length dystrophin. This approach could address limitations of current therapies and position Precision BioSciences as a leader in gene editing for rare genetic diseases. The trial's success could validate the company's ARCUS platform and attract further investment in its pipeline.
What we're watching
- Clinical Progress
- Whether PBGENE-DMD can demonstrate durable functional improvements in DMD patients.
- Regulatory Pathway
- The pace at which Precision BioSciences advances PBGENE-DMD through regulatory milestones.
- Competitive Positioning
- How Precision BioSciences differentiates its near full-length dystrophin approach from truncated microdystrophin therapies.
Related topics